Evotec AG: Fiscal year 2015 results presentation on 22 March 2016

Hamburg, Germany – 15 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for 2015 on Tuesday, 22 March 2016. The Company is going to hold a conference call to … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-fiscal-year-2015-results-presentation-on-22-march-2016-5348

Weiterlesen

Evotec achieves milestone in collaboration with Padlock Therapeutics

Evotec AG today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. („Padlock“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-milestone-in-collaboration-with-padlock-therapeutics-5346

Weiterlesen

Evotec to present at IR conference

Hamburg, Germany – 03 March 2016: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the BioCapital Europe 2016 in Amsterdam, The Netherlands, … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-present-at-ir-conference-5344

Weiterlesen

The preclinical clinical interface: A key to translational success in Oncology

Evotecs nächstes Webinar “The preclinical clinical interface: A key to translational success in Oncology” findet am Donnerstag, den 10. März 2016 um 10.00 Uhr EST / 15.00 Uhr GMT statt und wird unter anderem … Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/the-preclinical-clinical-interface-a-key-to-translational-success-in-oncology-5340

Weiterlesen

Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research

Evotec AG today announced that it has been awarded a research grant from The Michael J. Fox Foundation („MJFF“) to further develop Evotec’s TargetaSN (Targetalpha-synuclein) programme for the treatment of Parkinson’s disease. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-awarded-grant-from-the-michael-j-fox-foundation-for-parkinsons-research-5339

Weiterlesen

Evotec achieves important milestone in TargetAD collaboration with Janssen in Alzheimer's disease

Evotec AG today announced the achievement of an important milestone in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. („Janssen“) for the transition of a project into further drug discovery process. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-achieves-important-milestone-in-targetad-collaboration-with-janssen-in-alzheimers-disease-5335

Weiterlesen